bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Authors: Schoen Robert E. , Boardman Lisa A. , Cruz-Correa Marcia , Bansal Ajay , Kastenberg David , Hur Chin , Dzubinski Lynda , Kaufman Sharon F. , Rodriguez Luz M. , Richmond Ellen , Umar Asad , Szabo Eva , Salazar Andres , McKolanis John , Beatty Pamela , Pai Reetesh K. , Singhi Aatur D. , Jacqueline Camille M. , Bao Riuye , Diergaarde Brenda , McMurray Ryan P. , Strand Carrie , Foster Nathan R. , Zahrieh David M. , Limburg Paul J. , Finn Olivera J.
Published: April 2023

Endpoint titers of plasma antibodies at week 12 amongst vaccine responders
Figure S5 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Authors: Cole Alexander J. , Panesso-Gómez Santiago , Shah Jaynish S. , Ebai Tonge , Jiang Qi , Gumusoglu-Acar Ece , Bello Maya G. , Vlad Anda , Modugno Francesmary , Edwards Robert P. , Buckanovich Ronald J.
Published: April 2023

Supplementary Figure 5. Schematic of FST CRISPR KO guides and in vivo experiment. A. Binding of the two commercially available FST CRISPR guides to FST to mediate KO. B. Mice were injected with SKOV3 cells expressing FST sgRNA #2. Mice were then treated 3 times with 10mg/kg Taxol intraperitoneal Paclitaxel at days 7, 14 and 21. C Dissection of control mice presenting with multiple metastases and an FST-KO mice which showed no residual disease. White arrows point to sites of disease.
Data from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Authors: Cole Alexander J. , Panesso-Gómez Santiago , Shah Jaynish S. , Ebai Tonge , Jiang Qi , Gumusoglu-Acar Ece , Bello Maya G. , Vlad Anda , Modugno Francesmary , Edwards Robert P. , Buckanovich Ronald J.
Published: April 2023

AbstractPurpose:
We recently reported that the transcription factor NFATC4, in response to chemotherapy, drives cellular quiescence to increase ovarian cancer chemoresistance. The goal of this work was to better understand the mechanisms of NFATC4-driven ovarian cancer chemoresistance.
Experimental Design:
We used RNA sequencing to identify NFATC4-mediated differential gene expression. CRISPR-Cas9 and FST (follistatin)-neutralizing antibodies were used to assess impact of loss of FST function on cell proliferation and chemoresistance. ELISA was used to quantify FST induction in patient samples and in vitro in response to chemotherapy.
Results:
We found that NFATC4 upregulates FST mRNA and protein expression predominantly in quiescent cells and FST is further upregulated following chemotherapy treatment. FST acts in at least a paracrine manner to induce a p-ATF2–dependent quiescent phenotype and chemoresistance in non-quiescent cells. Consistent with this, CRISPR knockout (KO) of FST in ovarian cancer cells or antibody-mediated neutralization of FST sensitizes ovarian cancer cells to chemotherapy treatment. Similarly, CRISPR KO of FST in tumors increased chemotherapy-mediated tumor eradication in an otherwise chemotherapy-resistant tumor model. Suggesting a role for FST in chemoresistance in patients, FST protein in the abdominal fluid of patients with ovarian cancer significantly increases within 24 hours of chemotherapy exposure. FST levels decline to baseline levels in patients no longer receiving chemotherapy with no evidence of disease. Furthermore, elevated FST expression in patient tumors is correlated with poor progression-free, post–progression-free, and overall survival.
Conclusions:
FST is a novel therapeutic target to improve ovarian cancer response to chemotherapy and potentially reduce recurrence rates.
Supplementary Figure 1 from In Situ Vaccination with CD204 Gene-Silenced Dendritic Cell, not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer
Authors: Guo Chunqing , Yi Huanfa , Yu Xiaofei , Zuo Daming , Qian Jie , Yang Gary , Foster Barbara A. , Subjeck John R. , Sun Xiaolei , Mikkelsen Ross B. , Fisher Paul B. , Wang Xiang-Yang
Published: April 2023

PDF file, 1186K, Silencing SRA/CD204 enhances an inflammatory response in DCs stimulated with radiation-treated tumor cells.
Supplementary Methods from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo
Authors: Dasmahapatra Girija , Lembersky Dmitry , Son Minkyeong P. , Patel Hiral , Peterson Derick , Attkisson Elisa , Fisher Richard I. , Friedberg Jonathan W. , Dent Paul , Grant Steven
Published: April 2023

PDF file - 95K
Supplementary Figure and Table Legends from Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol
Authors: Riffell Jenna L. , Jänicke Reiner U. , Roberge Michel
Published: April 2023

Supplementary Figure and Table Legends from Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol
Supplementary Figure 2 from Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single-Agent Activity and Synergize with Cisplatin
Authors: Neher Tracy M. , Bodenmiller Diane , Fitch Richard W. , Jalal Shadia I. , Turchi John J.
Published: April 2023

PDF file - 78K
Supplementary Figure 3 from Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines
Authors: Santer Frédéric R. , Höschele Philipp P.S. , Oh Su Jung , Erb Holger H.H. , Bouchal Jan , Cavarretta Ilaria T. , Parson Walther , Meyers David J. , Cole Philip A. , Culig Zoran
Published: April 2023

Supplementary Figure 3 from Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines
Supplementary Table 1, Figures 1-2 from Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells
Authors: Zhang Chunyu , Elkahloun Abdel G. , Liao Hongling , Delaney Shannon , Saber Barbara , Morrow Betsy , Prendergast George C. , Hollander M. Christine , Gills Joell J. , Dennis Phillip A.
Published: April 2023

Supplementary Table 1, Figures 1-2 from Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells
Supplementary Table 1, Figure Legends 1-2 from The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
Authors: Chen Jun , Jin Sha , Abraham Vivek , Huang Xiaoli , Liu Bernard , Mitten Michael J. , Nimmer Paul , Lin Xiaoyu , Smith Morey , Shen Yu , Shoemaker Alexander R. , Tahir Stephen K. , Zhang Haichao , Ackler Scott L. , Rosenberg Saul H. , Maecker Heather , Sampath Deepak , Leverson Joel D. , Tse Chris , Elmore Steven W.
Published: April 2023

PDF file - 77K
Supplementary Figures 1-11, Supplementary Tables 1-2 from Chromatin Structure Predicts Epigenetic Therapy Responsiveness in Sarcoma
Authors: Mills Joslyn , Hricik Todd , Siddiqi Sara , Matushansky Igor
Published: April 2023

Supplementary Figures 1-11, Supplementary Tables 1-2 from Chromatin Structure Predicts Epigenetic Therapy Responsiveness in Sarcoma
Supplementary Figure 2 from Apigenin Induces Apoptosis in Human Leukemia Cells and Exhibits Anti-Leukemic Activity In Vivo
Authors: Budhraja Amit , Gao Ning , Zhang Zhuo , Son Young-Ok , Cheng Senping , Wang Xin , Ding Songze , Hitron Andrew , Chen Gang , Luo Jia , Shi Xianglin
Published: April 2023

PDF file - 2.2MB
Supplementary Table 1 from Tumor Suppressor MicroRNA-493 Decreases Cell Motility and Migration Ability in Human Bladder Cancer Cells by Downregulating RhoC and FZD4
Authors: Ueno Koji , Hirata Hiroshi , Majid Shahana , Yamamura Soichiro , Shahryari Varahram , Tabatabai Z. Laura , Hinoda Yuji , Dahiya Rajvir
Published: April 2023

PDF file - 4.6MB
Supplementary Figure Legend from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
Authors: Surriga Oliver , Rajasekhar Vinagolu K. , Ambrosini Grazia , Dogan Yildrim , Huang Ruimin , Schwartz Gary K.
Published: April 2023

PDF file - 89K
Supplementary Figure 3 from Targeting Olfactomedin-like 3 Inhibits Tumor Growth by Impairing Angiogenesis and Pericyte Coverage
Authors: Miljkovic-Licina Marijana , Hammel Philippe , Garrido-Urbani Sarah , Lee Boris P.-L. , Meguenani Mehdi , Chaabane Chiraz , Bochaton-Piallat Marie-Luce , Imhof Beat A.
Published: April 2023

PDF file - 2297K, In vitro t.End1.Vhigh cell sprouting assays
Supplementary Figures 1-2, Tables 1-2 from Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
Authors: Nam Hyun-Jin , Ching Keith A. , Kan Julie , Kim Hwang-Phill , Han Sae-Won , Im Seock-Ah , Kim Tae-You , Christensen James G. , Oh Do-Youn , Bang Yung-Jue
Published: April 2023

PDF file - 335K
Supplementary Figure 5 from Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer
Authors: Bhola Neil E. , Freilino Maria L. , Joyce Sonali C. , Sen Malabika , Thomas Sufi M. , Sahu Anirban , Cassell Andre , Chen Ching-Shih , Grandis Jennifer R.
Published: April 2023

PDF file, 289KB, Phosphorylated MAPK and AKT abrogated in C225-treated PDKM xenografts.
Supplementary Video 2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
Authors: Francia Giulio , Shaked Yuval , Hashimoto Kae , Sun John , Yin Melissa , Cesta Carolyn , Xu Ping , Man Shan , Hackl Christina , Stewart Julie , Uhlik Mark , Dantzig Anne H. , Foster F. Stuart , Kerbel Robert S.
Published: April 2023

AVI file - 5.6MB
Supplementary Figure 2 from Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer
Authors: Bhola Neil E. , Freilino Maria L. , Joyce Sonali C. , Sen Malabika , Thomas Sufi M. , Sahu Anirban , Cassell Andre , Chen Ching-Shih , Grandis Jennifer R.
Published: April 2023

PDF file, 76KB, Kinase-dead PDK1 decreases PGE2-induced growth increase.
Supplementary Figure 1 from EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
Authors: Arcila Maria E. , Nafa Khedoudja , Chaft Jamie E. , Rekhtman Natasha , Lau Christopher , Reva Boris A. , Zakowski Maureen F. , Kris Mark G. , Ladanyi Marc
Published: April 2023

PDF file - 106k, Outline of sequential genotyping algorithm followed in this study.
Supplementary Figure Legends from Interaction of the Sympathetic Nerve with Pancreatic Cancer Cells Promotes Perineural Invasion through the Activation of STAT3 Signaling
Authors: Guo Kun , Ma Qingyong , Li Junhui , Wang Zheng , Shan Tao , Li Wei , Xu Qinhong , Xie Keping
Published: April 2023

PDF file, 63KB
Supplementary Figure 1 from CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma
Authors: Wu Licun , Yun Zhihong , Tagawa Tetsuzo , Rey-McIntyre Katrina , de Perrot Marc
Published: April 2023

PDF file, 34KB, Response of xenograft tumors to current chemotherapy.
Supplementary Figure 1 from The Cannabinoid WIN 55,212-2 Decreases Specificity Protein Transcription Factors and the Oncogenic Cap Protein eIF4E in Colon Cancer Cells
Authors: Sreevalsan Sandeep , Safe Stephen
Published: April 2023

PDF - 635KB, Inhibition of CCD-18Co growth (A) and PP2A mediated effects of WIN on Sp proteins and ZBTB10 expression in RKO cells (B - E).
Supplementary Figure 8 from A Monoclonal Antibody against Human Notch1 Ligand–Binding Domain Depletes Subpopulation of Putative Breast Cancer Stem–like Cells
Authors: Sharma Ankur , Paranjape Anurag N. , Rangarajan Annapoorni , Dighe Rajan R.
Published: April 2023

PDF file - 33K
Supplementary Figures 1 - 2, Tables 1 - 2 from Selective Disruption of Rb–Raf-1 Kinase Interaction Inhibits Pancreatic Adenocarcinoma Growth Irrespective of Gemcitabine Sensitivity
Authors: Treviño José G. , Verma Monika , Singh Sandeep , Pillai Smitha , Zhang Dongyu , Pernazza Daniele , Sebti Said M. , Lawrence Nicholas J. , Centeno Barbara A. , Chellappan Srikumar P.
Published: April 2023

PDF file - 1279K, Supplementary Figure 1. PANC-1 and Mia-PaCa cells are highly sensitive to RRD-251. Supplementary Figure 2. RRD-251 enhances the pro-apoptotic effects of gemcitabine. TABLE 1. Varying sensitivity of pancreatic cancer cells to RRD-251. Supplementary Table 2: RRD-251 enhances early and late apoptosis.
Supplementary Figure Legends from ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non–Small Cell Lung Cancer Expressing EML4-ALK
Authors: Sun Yunguang , Nowak Kamila A. , Zaorsky Nicholas G. , Winchester Chia-Lin , Dalal Kunal , Giacalone Nicholas J. , Liu Ningbo , Werner-Wasik Maria , Wasik Mariusz A. , Dicker Adam P. , Lu Bo
Published: April 2023

PDF File - 57K, Legends for Supplementary Figures 1-3.
Supplementary Table 1 from Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9
Authors: Petrul Heike M. , Schatz Christoph A. , Kopitz Charlotte C. , Adnane Lila , McCabe Timothy J. , Trail Pamela , Ha Sha , Chang Yong S. , Voznesensky Andrei , Ranges Gerald , Tamburini Paul P.
Published: April 2023

PDF file - 24K, Affinities of different anti-CA9 antibodies as determined by surface plasmon resonance.
Supplementary Materials and Methods from Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9
Authors: Petrul Heike M. , Schatz Christoph A. , Kopitz Charlotte C. , Adnane Lila , McCabe Timothy J. , Trail Pamela , Ha Sha , Chang Yong S. , Voznesensky Andrei , Ranges Gerald , Tamburini Paul P.
Published: April 2023

PDF file - 106K, Anti-CAIX ADC Supplement.
Supplementary Figure 5 from Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9
Authors: Petrul Heike M. , Schatz Christoph A. , Kopitz Charlotte C. , Adnane Lila , McCabe Timothy J. , Trail Pamela , Ha Sha , Chang Yong S. , Voznesensky Andrei , Ranges Gerald , Tamburini Paul P.
Published: April 2023

PDF file - 82K, Anti-CAIX Western blot of tumor lysates.
Supplementary Figure 3 from Identification and Characterization of MEL-3, a Novel AR Antagonist That Suppresses Prostate Cancer Cell Growth
Authors: Helsen Christine , Marchand Arnaud , Chaltin Patrick , Munck Sebastian , Voet Arnout , Verstuyf Annemieke , Claessens Frank
Published: April 2023

PDF file, 37KB, MEL-3 has no agonistic properties on ClARE.
Supplementary Figure 2 from Identification and Characterization of MEL-3, a Novel AR Antagonist That Suppresses Prostate Cancer Cell Growth
Authors: Helsen Christine , Marchand Arnaud , Chaltin Patrick , Munck Sebastian , Voet Arnout , Verstuyf Annemieke , Claessens Frank
Published: April 2023

PDF file, 55KB, ClARE responds to androgen-like substances.
Supplementary Figure Legend from Thermal Targeting of an Acid-Sensitive Doxorubicin Conjugate of Elastin-like Polypeptide Enhances the Therapeutic Efficacy Compared with the Parent Compound In Vivo
Authors: Moktan Shama , Perkins Eddie , Kratz Felix , Raucher Drazen
Published: April 2023

PDF file, 35KB.
Supplementary Figure 1 from Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
Authors: Clark Caroline C. , Weitzel Jeffrey N. , O'Connor Timothy R.
Published: April 2023

PDF file, 161KB, SUPPLEMENTARY FIGURE S1. Clonogenic cell survival of WT and Brca mESCs and inhibition of human BRCA-deficient or -complemented cell proliferation after treatment with cisplatin alone or in combination with ABT-888. (A) Cisplatin structure. For WT (AB2.2, Brca) Brca1 (Brca1-/-) and Brca2 (Brca2-/-) mESCs were treated for 48 h with the indicated drugs and concentrations and survival assessed using colony formation. (B) cisplatin and (C) ABT-888 with cisplatin. Data represent average of triplicate measurements. For (D-G), cell growth as assessed by MTT assay at 72 h for D-G post drug treatment. Percentage of growth inhibition of HCC1937 or HCC1937+BRCA1 cells after treatment with (D) cisplatin or (E) ABT-888 (200 μM)/cisplatin combination. Percentage of growth inhibition of EUFA423F and EUFA423F+BRCA2 cells after treatment with (F) cisplatin or (G) 12.5 μM ABT-888/ cisplatin combination. The percentage of cells that exhibited growth inhibition after 72 h of continuous drug treatment was compared to that of untreated cells. Data represent the average of at least triplicate samples. Error bars, mean + SEM.
Supplementary Figure 3 from Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation
Authors: Kim Sun Mi , Kwon Oh-Joon , Hong Yun Kyoung , Kim Joo Hang , Solca Flavio , Ha Sang-Jun , Soo Ross A. , Christensen James G. , Lee Ji Hyun , Cho Byoung Chul
Published: April 2023

PDF file, 22K, Activation of JAK family by treatment of afatinib.
Supplementary Figure 2 from Differential Induction of Apoptosis and Senescence by the DNA Methyltransferase Inhibitors 5-Azacytidine and 5-Aza-2′-Deoxycytidine in Solid Tumor Cells
Authors: Venturelli Sascha , Berger Alexander , Weiland Timo , Essmann Frank , Waibel Michaela , Nuebling Tina , Häcker Sabine , Schenk Martin , Schulze-Osthoff Klaus , Salih Helmut R. , Fulda Simone , Sipos Bence , Johnstone Ricky W. , Lauer Ulrich M. , Bitzer Michael
Published: April 2023

PDF file - 32K, Induction of apoptosis and activation of caspase 3/7 by 5-aza- CR but not 5-aza-dC in hepatoma cell lines.
Supplementary Table 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Authors: Kalous Ondrej , Conklin Dylan , Desai Amrita J. , O'Brien Neil A. , Ginther Charles , Anderson Lee , Cohen David J. , Britten Carolyn D. , Taylor Ian , Christensen James G. , Slamon Dennis J. , Finn Richard S.
Published: April 2023

PDF file, 68K, Quantification of proteins from Western blots in Figure 3 by densitometry using ImageJ software.
Supplementary Table 2 from Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo
Authors: Thomas Christian , Lamoureux Francois , Crafter Claire , Davies Barry R. , Beraldi Eliana , Fazli Ladan , Kim Soojin , Thaper Daksh , Gleave Martin E. , Zoubeidi Amina
Published: April 2023

PDF - 84KB, AZD5363 activity in prostate cancer cell lines in vitro
Supplementary Figure 2 from Attenuation of Argininosuccinate Lyase Inhibits Cancer Growth via Cyclin A2 and Nitric Oxide
Authors: Huang Hau-Lun , Hsu Hui-Ping , Shieh Shu-Chu , Chang Yung-Sheng , Chen Wei-Ching , Cho Chien-Yu , Teng Chiao-Fang , Su Ih-Jen , Hung Wen-Chun , Lai Ming-Derg
Published: April 2023

PDF - 2780 KB, ASL promoter activity induced by ER stress
Supplementary Figure 1 from A Urokinase Receptor–Derived Peptide Inhibiting VEGF-Dependent Directional Migration and Vascular Sprouting
Authors: Bifulco Katia , Longanesi-Cattani Immacolata , Liguori Eleonora , Arra Claudio , Rea Domenica , Masucci Maria Teresa , De Rosa Mario , Pavone Vincenzo , Stoppelli Maria Patrizia , Carriero Maria Vincenza
Published: April 2023

PDF file, 2456K, Proliferation curves of HUVEC as generated by xCELLigence RTCA seeding 2x103 cells/well during a period of 72 hours, in the presence of 8% FBS, or 40ng/ml VEGF plus or minus 10 muM ERFR, 10nM RERF or 10 muM RERF. Data are the mean+SD of one experiment, performed in quadruplicate.
Supplementary Figures 1 - 10 from Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening
Authors: Rickles Richard J. , Tam Winnie F. , Giordano Thomas P. , Pierce Laura T. , Farwell Melissa , McMillin Douglas W. , Necheva Antoaneta , Crowe David , Chen Mei , Avery William , Kansra Vikram , Nawrocki Steffan T. , Carew Jennifer S. , Giles Francis J. , Mitsiades Constantine S. , Borisy Alexis A. , Anderson Kenneth C. , Lee Margaret S.
Published: April 2023

PDF file, 849KB.
Supplementary Table S4 from miRNA-100 Inhibits Human Bladder Urothelial Carcinogenesis by Directly Targeting mTOR
Authors: Xu Chuanliang , Zeng Qinsong , Xu Weidong , Jiao Li , Chen Yanqiong , Zhang Zhensheng , Wu Chengyao , Jin Taile , Pan Anyin , Wei Rongchao , Yang Bo , Sun Yinghao
Published: April 2023

PDF file - 126KB, Significantly dysregulated miRNAs in muscle-invasive BC
Supplementary Figure Legend and Methods from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Authors: Kani Kian , Faca Vitor M. , Hughes Lindsey D. , Zhang Wenxuan , Fang Qiaojun , Shahbaba Babak , Luethy Roland , Erde Jonathan , Schmidt Joanna , Pitteri Sharon J. , Zhang Qing , Katz Jonathan E. , Gross Mitchell E. , Plevritis Sylvia K. , McIntosh Martin W. , Jain Anjali , Hanash Samir , Agus David B. , Mallick Parag
Published: April 2023

PDF file, 83KB.
Supplementary Table 2 from PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Authors: Saha Manujendra N. , Jiang Hua , Yang Yijun , Reece Donna , Chang Hong
Published: April 2023

PDF - 102KB, Supplementary Table 2. Differential expression of genes in MM.1S cells treated with PRIMA-1Met
Supplementary Figure 1 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
Authors: Nakagawa Takayuki , Takeuchi Shinji , Yamada Tadaaki , Nanjo Shigeki , Ishikawa Daisuke , Sano Takako , Kita Kenji , Nakamura Takahiro , Matsumoto Kunio , Suda Kenichi , Mitsudomi Tetsuya , Sekido Yoshitaka , Uenaka Toshimitsu , Yano Seiji
Published: April 2023

PDF file, 479K, Supplementary Figure S1 Growth inhibitory activity of WZ4002 and erlotinib on NSCLC cell lines harboring EGFR mutations.
Supplementary Figure 4 from MUC13 Mucin Augments Pancreatic Tumorigenesis
Authors: Chauhan Subhash C. , Ebeling Mara C. , Maher Diane M. , Koch Michael D. , Watanabe Akira , Aburatani Hiroyuki , Lio Yuhlong , Jaggi Meena
Published: April 2023

PDF file - 1.8MB
Supplementary Figure 3 from MUC13 Mucin Augments Pancreatic Tumorigenesis
Authors: Chauhan Subhash C. , Ebeling Mara C. , Maher Diane M. , Koch Michael D. , Watanabe Akira , Aburatani Hiroyuki , Lio Yuhlong , Jaggi Meena
Published: April 2023

PDF file - 1.3MB
Supplementary Figure 1 from Immunotherapy for Hepatoma Using a Dual-Function Vector with Both Immunostimulatory and Pim-3–Silencing Effects
Authors: Guo Qie , Lan Peixiang , Yu Xin , Han Qiuju , Zhang Jian , Tian Zhigang , Zhang Cai
Published: April 2023

PDF - 44K, Figure S1. The expression of Pim-3 in mouse hepatoma cell lines and human hepatocellular carcinoma tissues. The expression of Pim-3 in murine hepatoma cell lines H22 and Hepa1-6 and the normal liver cell line BNL.CL2 as measured by semi-quantitative RT-PCR (A) and Western blotting (B). The expression of Pim-3 in human hepatocellular carcinoma tissues (T) and nontumor tissues (N) detected by real-time PCR (C) and Western blotting (D).
Supplementary Figure Legend from Apoptotic Circulating Tumor Cells in Early and Metastatic Breast Cancer Patients
Authors: Kallergi Galatea , Konstantinidis Georgios , Markomanolaki Harris , Papadaki Maria A. , Mavroudis Dimitris , Stournaras Christos , Georgoulias Vassilis , Agelaki Sofia
Published: April 2023

PDF file - 60K
Supplementary Figure 1 from PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer
Authors: Ostapoff Katherine T. , Awasthi Niranjan , Kutluk Cenik Bercin , Hinz Stefan , Dredge Keith , Schwarz Roderich E. , Brekken Rolf A.
Published: April 2023

PDF - 153K, Example histology of liver metastases in the mPDAC model. Liver sections were stained with H&E. Scale bar, 100 um.
Supplementary Methods from In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells
Authors: Dasmahapatra Girija , Patel Hiral , Friedberg Johnathan , Quayle Steven N. , Jones Simon S. , Grant Steven
Published: April 2023

Supplementary Methods.
Supplemental Figure 2 from CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Authors: Chen Robert , Hou Jessie , Newman Edward , Kim Young , Donohue Cecile , Liu Xueli , Thomas Sandra H. , Forman Stephen J. , Kane Susan E.
Published: April 2023

Supplemental Figure 2. Karpas-R cultured in the absence of BV have decreased IC50.
Supplementary Table 1 and Supplementary Figures 1 to 3 from Bisphosphonamidate Clodronate Prodrug Exhibits Selective Cytotoxic Activity against Melanoma Cell Lines
Authors: Webster Marie R. , Kamat Chandrashekhar , Connis Nick , Zhao Ming , Weeraratna Ashani T. , Rudek Michelle A. , Hann Christine L. , Freel Meyers Caren L.
Published: April 2023

PDF - 295K, Table S1. In vitro effects of CLO prodrug in NCI-60 cell screen. Table S2. In vitro effects of the CLO prodrug on SK-Mel-5 and UACC-62 melanoma cells. Figure S1. Bisphosphonamidate prodrugs are cell permeable and undergo intracellular activation in UACC-62 cells. Figure S2. CLO prodrug does not affect the viability of human keratinocytes and peripheral blood mononuclear cells. Figure S3. Intratumoral delivery of clodronate has no antitumor activity.
Supplementary Figure S4 from Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer
Authors: Arora Arvind , Abdel-Fatah Tarek M.A. , Agarwal Devika , Doherty Rachel , Moseley Paul M. , Aleskandarany Mohammed A. , Green Andrew R. , Ball Graham , Alshareeda Alaa T. , Rakha Emad A. , Chan Stephen Y.T. , Ellis Ian O. , Madhusudan Srinivasan
Published: April 2023

BLM-Rad51 co-expression and survival.
Supplementary Figure S2 from Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer
Authors: Arora Arvind , Abdel-Fatah Tarek M.A. , Agarwal Devika , Doherty Rachel , Moseley Paul M. , Aleskandarany Mohammed A. , Green Andrew R. , Ball Graham , Alshareeda Alaa T. , Rakha Emad A. , Chan Stephen Y.T. , Ellis Ian O. , Madhusudan Srinivasan
Published: April 2023

Western blots and immunohistochemistry.
Supplementary Fig. 1 from Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300
Authors: Uttarkar Sagar , Dukare Sandeep , Bopp Bertan , Goblirsch Michael , Jose Joachim , Klempnauer Karl-Heinz
Published: April 2023

Suppl. Fig. 1. Analysis of the c-Myb/CBP interaction by microscale thermophoresis.
Supplementary Methods and Supplementary Figure Legend from Novel Target for Peptide-Based Imaging and Treatment of Brain Tumors
Authors: Hyvönen Maija , Enbäck Juulia , Huhtala Tuulia , Lammi Johanna , Sihto Harri , Weisell Janne , Joensuu Heikki , Rosenthal-Aizman Katri , El-Andaloussi Samir , Langel Ulo , Närvänen Ale , Bergers Gabriele , Laakkonen Pirjo
Published: April 2023

PDF - 72K, Supplementary Methods and Legend for Supplementary Figures 1 and 2.
Supplementary Figure 1 from Novel Target for Peptide-Based Imaging and Treatment of Brain Tumors
Authors: Hyvönen Maija , Enbäck Juulia , Huhtala Tuulia , Lammi Johanna , Sihto Harri , Weisell Janne , Joensuu Heikki , Rosenthal-Aizman Katri , El-Andaloussi Samir , Langel Ulo , Närvänen Ale , Bergers Gabriele , Laakkonen Pirjo
Published: April 2023

PDF - 49K, MDGI expression increased binding of the CooP phage.
Supplementary Figure 3 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Authors: Stone Andrew , Cowley Mark J. , Valdes-Mora Fatima , McCloy Rachael A. , Sergio C. Marcelo , Gallego-Ortega David , Caldon C. Elizabeth , Ormandy Christopher J. , Biankin Andrew V. , Gee Julia M.W. , Nicholson Robert I. , Print Cristin G. , Clark Susan J. , Musgrove Elizabeth A.
Published: April 2023

PDF - 459KB, BCL-2 Methylation status in cancer vs normal tissue.
Supplementary Figure 3 from Coleusin Factor, a Novel Anticancer Diterpenoid, Inhibits Osteosarcoma Growth by Inducing Bone Morphogenetic Protein-2–Dependent Differentiation
Authors: Geng Shuo , Sun Bo , Lu Ran , Wang Jingze
Published: April 2023

PDF - 727K, BMP-2 production is up-regulated in xenografted osteosarcoma cells after CF administration.
Supplementary Figure 1 from Coleusin Factor, a Novel Anticancer Diterpenoid, Inhibits Osteosarcoma Growth by Inducing Bone Morphogenetic Protein-2–Dependent Differentiation
Authors: Geng Shuo , Sun Bo , Lu Ran , Wang Jingze
Published: April 2023

PDF - 442K, CF treatment does not induce apoptosis of osteosarcoma cells.
Supplementary Methods from Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
Authors: Rozan Caroline , Cornillon Amélie , Pétiard Corinne , Chartier Martine , Behar Ghislaine , Boix Charlotte , Kerfelec Brigitte , Robert Bruno , Pèlegrin André , Chames Patrick , Teillaud Jean-Luc , Baty Daniel
Published: April 2023

PDF file - 120K
Supplementary Figures 1 - 4 from Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism
Authors: Nguyen Tri K. , Grant Steven
Published: April 2023

PDF file - 438K, Supplementary Figure 1: SCH727965 blocks induction of XBP-1s and Grp78; Supplementary Figure 2: Knockdown CDK1 or CDK5 reduced nuclear XBP-1s expression; Supplementary Figure 3: Knockdown CDK2 or CDK9 exhibits very modestly or no changes in XBP-1s or Grp78 following Tg exposure; Supplementary Figure 4: Knockdown CDK1 or CDK5 increases sensitivity to ER stress inducers.
Supplementary Figure 1 from MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
Authors: Kitamura Kazuhiro , Seike Masahiro , Okano Tetsuya , Matsuda Kuniko , Miyanaga Akihiko , Mizutani Hideaki , Noro Rintaro , Minegishi Yuji , Kubota Kaoru , Gemma Akihiko
Published: April 2023

PDF file - 146K, Supplementary Figure S1: Differences in miR-134/487b/655 expression between EMT-positive and EMT-negative cells in eight lung adenocarcinoma cell lines.
Supplementary Table S2 from Triptolide Induces the Expression of miR-142-3p: A Negative Regulator of Heat Shock Protein 70 and Pancreatic Cancer Cell Proliferation
Authors: MacKenzie Tiffany N. , Mujumdar Nameeta , Banerjee Sulagna , Sangwan Veena , Sarver Aaron , Vickers Selwyn , Subramanian Subbaya , Saluja Ashok K.
Published: April 2023

Supplementary Table S2 - PDF file 49K, Statistics miRNAs from microarray which are known to play a role in PDAC
Supplementary Figure 5 from Triptolide Induces the Expression of miR-142-3p: A Negative Regulator of Heat Shock Protein 70 and Pancreatic Cancer Cell Proliferation
Authors: MacKenzie Tiffany N. , Mujumdar Nameeta , Banerjee Sulagna , Sangwan Veena , Sarver Aaron , Vickers Selwyn , Subramanian Subbaya , Saluja Ashok K.
Published: April 2023

Supplementary Figure 5 - PDF file 62K, HSF1 and miR-142-3p independently regulate HSPA1B (HSP70) and mediate triptolide-induced suppression of PDAC proliferation
Supplementary Figure 2 from Triptolide Induces the Expression of miR-142-3p: A Negative Regulator of Heat Shock Protein 70 and Pancreatic Cancer Cell Proliferation
Authors: MacKenzie Tiffany N. , Mujumdar Nameeta , Banerjee Sulagna , Sangwan Veena , Sarver Aaron , Vickers Selwyn , Subramanian Subbaya , Saluja Ashok K.
Published: April 2023

Supplementary Figure 2 - PDF file 156K, Validation of miRNA microarray by real-time PCR
Supplemental Methods from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer
Authors: Karginova Olga , Siegel Marni B. , Van Swearingen Amanda E.D. , Deal Allison M. , Adamo Barbara , Sambade Maria J. , Bazyar Soha , Nikolaishvili-Feinberg Nana , Bash Ryan , O'Neal Sara , Sandison Katie , Parker Joel S. , Santos Charlene , Darr David , Zamboni William , Lee Yueh Z. , Miller C. Ryan , Anders Carey K.
Published: April 2023

This file contains additional details on the microarray analysis and normalization.
Supplemental Figures S1-S9 from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer
Authors: Karginova Olga , Siegel Marni B. , Van Swearingen Amanda E.D. , Deal Allison M. , Adamo Barbara , Sambade Maria J. , Bazyar Soha , Nikolaishvili-Feinberg Nana , Bash Ryan , O'Neal Sara , Sandison Katie , Parker Joel S. , Santos Charlene , Darr David , Zamboni William , Lee Yueh Z. , Miller C. Ryan , Anders Carey K.
Published: April 2023

This file contains the compiled Supplemental Figures S1-S9. Figure S1 is a flowchart describing the process of normalizing the microarray data for the SUM149 model for the different scanners used. Figure S2 depicts the scanner differences in the microarray data for the SUM149 model before and after normalization. Figure S3 is a flowchart depicting the analytical process used to analyze and compare the SUM149 and MDA-MB-436 models microarray results, and Figure S4 shows the difference in scale between models before and after the scaling process for visual comparison of the SUM149 and MDA-MB-436 models. Figure S5 demonstrates the lack of survival benefit of Carboplatin +/- ABT88 in the two BRCA-wt models, MDA-MB-468 and MDA-MB-231BR. Figure S6 contains representative images of IHC cC3 staining for the BRCA-wt model, MDA-MB-468. Figure S7 shows the unsupervised clustering of the BRCA-mut SUM149 and MDA-MB-436 models with treatment. Figure S8 contains the supervised clustering based on carboplatin treatment in these two models. Figure S9 demonstrates the expression levels of the 38 commonly regulated genes in both models with carboplatin treatment.
Supplemental Figure Legends from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer
Authors: Karginova Olga , Siegel Marni B. , Van Swearingen Amanda E.D. , Deal Allison M. , Adamo Barbara , Sambade Maria J. , Bazyar Soha , Nikolaishvili-Feinberg Nana , Bash Ryan , O'Neal Sara , Sandison Katie , Parker Joel S. , Santos Charlene , Darr David , Zamboni William , Lee Yueh Z. , Miller C. Ryan , Anders Carey K.
Published: April 2023

This file contains the figure legends for Supplemental Figures S1-S9.
Supplementary Figures 1 - 6 from A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein
Authors: Pop Marius S. , Stransky Nicolas , Garvie Colin W. , Theurillat Jean-Philippe , Hartman Emily C. , Lewis Timothy A. , Zhong Cheng , Culyba Elizabeth K. , Lin Fallon , Daniels Douglas S. , Pagliarini Raymond , Ronco Lucienne , Koehler Angela N. , Garraway Levi A.
Published: April 2023

PDF file - 1496K, Figure S1 - control expression and SMM hits representation; luciferase assay with MITF for BRD32048 and luciferase assay using BRD32048 analogs. Figure S2 - SPR data control graphs for TBX21 reference experiment. Figure S3 alternative SPR data for antibody reference; RU signals for additional reference surfaces. Figure S4 - ETV1 silencing validation data at mRNA and protein levels; alternative view of LNCaP signatures overlap; the proliferative effects of BRD32048 in LNCaP cell line and QPCR validation of BRD32048 inhibited targets. Figure S5 - control expression of indicated proteins and control invasion assays; - proliferation of cell lines in the presence of BRD32048. Figure S6 supportive mechanistic evidence such as ETV1-DNA interaction; BRD32048-induced loss of endogenous ETV1 and the effect of BRD32048 on an acetylation-deficient ETV1 mutant.
Supplementary Table 2 from Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models
Authors: Benetatos Christopher A. , Mitsuuchi Yasuhiro , Burns Jennifer M. , Neiman Eric M. , Condon Stephen M. , Yu Guangyao , Seipel Martin E. , Kapoor Gurpreet S. , LaPorte Matthew G. , Rippin Susan R. , Deng Yijun , Hendi Mukta S. , Tirunahari Pavan K. , Lee Yu-Hua , Haimowitz Thomas , Alexander Matthew D. , Graham Martin A. , Weng David , Shi Yigong , McKinlay Mark A. , Chunduru Srinivas K.
Published: April 2023

XLS file - 45KB, Sensitivity of a 111 cell line panel to birinapant as a single agent and in combination with TNF or TRAIL.
Supplementary Figure 2 from Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth
Authors: Campbell Veronica T. , Nadesan Puviindran , Ali S. Amanda , Wang Chang Ye Yale , Whetstone Heather , Poon Raymond , Wei Qingxia , Keilty John , Proctor Jennifer , Wang Lauren W. , Apte Suneel S. , McGovern Karen , Alman Benjamin A. , Wunder Jay S.
Published: April 2023

PDF - 427K, Representative image of a hematoxylin and esosin stained primary chondrosarcoma xenograft. The image shows a typical appearance of low cellularity (blue nuclei) with considerable extracellular matrix between the cells and no obvious tumor stroma.
Supplementary Table 1 from Regulation of SRC Kinases by microRNA-3607 Located in a Frequently Deleted Locus in Prostate Cancer
Authors: Saini Sharanjot , Majid Shahana , Shahryari Varahram , Tabatabai Z. Laura , Arora Sumit , Yamamura Soichiro , Tanaka Yuichiro , Dahiya Rajvir , Deng Guoren
Published: April 2023

PDF - 68K, Clinicopathological data for matched LCM-microdissected tissues used for real-time PCR analysis of miR-3607 expression in Figure 1.
Supplementary Figure 3 from Regulation of SRC Kinases by microRNA-3607 Located in a Frequently Deleted Locus in Prostate Cancer
Authors: Saini Sharanjot , Majid Shahana , Shahryari Varahram , Tabatabai Z. Laura , Arora Sumit , Yamamura Soichiro , Tanaka Yuichiro , Dahiya Rajvir , Deng Guoren
Published: April 2023

PDF - 277K, Prostate cancer cell lines (LNCaP, PC3, Du145) treated with docetaxel at varying concentrations and time periods (6 hrs, 24 hrs) followed by miR-3607 expression analysis by real-time PCR.
Supplementary Materials and Methods and Supplementary Figures 1 through 5 from Urokinase Plasminogen Activator System–Targeted Delivery of Nanobins as a Novel Ovarian Cancer Therapy
Authors: Zhang Yilin , Kenny Hilary A. , Swindell Elden P. , Mitra Anirban K. , Hankins Patrick L. , Ahn Richard W. , Gwin Katja , Mazar Andrew P. , O'Halloran Thomas V. , Lengyel Ernst
Published: April 2023

PDF - 469KB, Supplementary Materials & Methods; Supplementary Figure S1: Specific uptake of ATN-291-NB(Ni,As) in ovarian cancer cells; Supplementary Figure S2: Confocal studies of early apoptosis in HeyA8 cells treated with nanobins; Supplementary Figure S3: Targeted delivery using a urokinase antibody (ATN-291) does not inhibit uPA enzymatic activity in vitro; Supplementary Figure S4: Immunohistochemical analysis of the HeyA8 xenograft tumors upon the treatments of nanobins in vivo; Supplementary Figure S5: Organ function of mice treated by ATN-291-NB(Ni,As).
Supplementary Figure 5 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Authors: Kai Kazuharu , Kondo Kimie , Wang Xiaoping , Xie Xuemei , Pitner Mary K. , Reyes Monica E. , Torres-Adorno Angie M. , Masuda Hiroko , Hortobagyi Gabriel N. , Bartholomeusz Chandra , Saya Hideyuki , Tripathy Debu , Sen Subrata , Ueno Naoto T.
Published: April 2023

Knockout of p53 in HCT116 colon cancer cells treated with KW-2450.
Supplementary Figures 1 through 5 from Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer
Authors: Guerrouahen Bella S. , Pasquier Jennifer , Kaoud Nadine Abu , Maleki Mahtab , Beauchamp Marie-Claude , Yasmeen Amber , Ghiabi Pegah , Lis Raphael , Vidal Fabien , Saleh Ahmed , Gotlieb Walter H. , Rafii Shahin , Rafii Arash
Published: April 2023

Supplementary figure S1: representative western blot showing Akt (S473) phosphorylation in HUVEC incubated with the conditioned medium (CM) of SKOV-3 and GOC-A2. Supplementary figure S2: expression of VEGF-A in HUVEC and E4+EC and VEGFR expression in HUVEC and E4+EC. Supplementary figure S3: functional assays performed in the presence of VEGF-A and bevacizumab in HUVECs. Microvascular endothelial cells isolated from ovarian tissue (HOMEC) were treated by bevacizumab to assess growth inhibition. Supplementary figure S4: involvements of Akt and FGF-2/FGFR axis in the resistance to bevacizumab in the activated endothelium. Supplementary figure S5: FGF-2 decreases the sensitivity of HUVEC to bevacizumab.
Supplementary Figure Legends from Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer
Authors: Guerrouahen Bella S. , Pasquier Jennifer , Kaoud Nadine Abu , Maleki Mahtab , Beauchamp Marie-Claude , Yasmeen Amber , Ghiabi Pegah , Lis Raphael , Vidal Fabien , Saleh Ahmed , Gotlieb Walter H. , Rafii Shahin , Rafii Arash
Published: April 2023

Legends for Supplementary Figures.
Supplementary Figure 3 from Moguntinones—New Selective Inhibitors for the Treatment of Human Colorectal Cancer
Authors: Maderer Annett , Plutizki Stanislav , Kramb Jan-Peter , Göpfert Katrin , Linnig Monika , Khillimberger Katrin , Ganser Christopher , Lauermann Eva , Dannhardt Gerd , Galle Peter R. , Moehler Markus
Published: April 2023

PDF file - 42K, Supplementary Figure 3. Effects of Moguntinon 19 on induction of apoptosis during 7 days kinetic.
Supplemental Figure Legends from Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma
Authors: Panka David J. , Buchbinder Elizabeth , Giobbie-Hurder Anita , Schalck Aislyn P. , Montaser-Kouhsari Laleh , Sepehr Alireza , Lawrence Donald P. , McDermott David F. , Cohen Rachel , Carlson Alexander , Wargo Jennifer A. , Merritt Ryan , Seery Virginia J. , Hodi F. Stephen , Gunturi Anasuya , Fredrick Dennie , Atkins Michael B. , Iafrate A. John , Flaherty Keith T. , Mier James W. , Sullivan Ryan J.
Published: April 2023

Supplemental Figure Legends from Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma
Supplementary Figure 4 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Authors: Gross Matt I. , Demo Susan D. , Dennison Jennifer B. , Chen Lijing , Chernov-Rogan Tania , Goyal Bindu , Janes Julie R. , Laidig Guy J. , Lewis Evan R. , Li Jim , MacKinnon Andrew L. , Parlati Francesco , Rodriguez Mirna L.M. , Shwonek Peter J. , Sjogren Eric B. , Stanton Timothy F. , Wang Taotao , Yang Jinfu , Zhao Frances , Bennett Mark K.
Published: April 2023

PDF - 125K, Supplementary Figure S4. Markers of glutamine utilization are increased in TNBC cell lines relative to receptor-positive cell lines.
Supplementary Figure 2 from XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer
Authors: Cheng Yan , Holloway Michael P. , Nguyen Kevin , McCauley Dilara , Landesman Yosef , Kauffman Michael G. , Shacham Sharon , Altura Rachel A.
Published: April 2023

PDF file - 53K, Serum levels of KPT-330 in mice.
Supplementary Figure 1 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
Authors: Cheung Arthur Kwok Leung , Yan Ip Joseph Chok , Lung Hong Lok , Wu Jim Zhen , Tsao Sai Wah , Lung Maria Li
Published: April 2023

PDF file - 1180K, Representative images of IHC staining of mouse tumor treated with vehicle control and Ro5203280.
Supplementary Figure 1 from Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
Authors: Acquaviva Jaime , Smith Donald L. , Jimenez John-Paul , Zhang Chaohua , Sequeira Manuel , He Suqin , Sang Jim , Bates Richard C. , Proia David A.
Published: April 2023

PDF file - 654K, Combinatorial activity of ganetespib with BRAF and MEK inhibitors in mutant BRAF V600E melanoma cells.
Supplementary Figures 1-6 from Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth
Authors: Huang Jie , Hu Wei , Hu Limin , Previs Rebecca A. , Dalton Heather J. , Yang Xiao-Yun , Sun Yunjie , McGuire Michael , Rupaimoole Rajesha , Nagaraja Archana S. , Kang Yu , Liu Tao , Nick Alpa M. , Jennings Nicholas B. , Coleman Robert L. , Jaffe Robert B. , Sood Anil K.
Published: April 2023

Supplementary Figure 1. Representative OVCAR3-inoculated mice after aflibercept, Dll4-Fc, and the combination. Supplementary Figure 2. In vivo study of Dll4 blockade, aflibercept, and docetaxel, alone and in combinations, in A2780 and HeyA8 models. Supplementary Figure 3. Immunohistochemical staining of CX3CL1 in the tumor stroma of mice inoculated with A2780 ovarian cancer cells. Supplementary Figure 4. Quantitative real-time PCR of CX3CL1 expression in A2780 cells cultured with primary dendritic cells isolated from C57/BL6 mice. Supplementary Figure 5. ELISA analysis of plasma IFN-gamma in the mice inoculated with A2780 ovarian cancer cells. Supplementary Figure 6. RT-PCR analysis of E-cadherin expression in tumors (tumor cells and stroma) obtained from A2780 mice treated with a single agent or a combination.
Supplementary Materials and Methods from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model
Authors: Sia Kian Chuan , Huynh Hung , Chung Alexander Yaw Fui , Ooi London Lucien Peng Jin , Lim Kiat Hon , Hui Kam Man , Lam Paula Yeng Po
Published: April 2023

Supplementary Materials and Methods - PDF file 94K, Supplementary Materials and Methods including helper virus-free packaging, isolation of single cells suspension, immunofluorescent (IF) staining, immunohistochemical (IHC) staining and cell cycle analysis
Supplementary Figure S8 from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model
Authors: Sia Kian Chuan , Huynh Hung , Chung Alexander Yaw Fui , Ooi London Lucien Peng Jin , Lim Kiat Hon , Hui Kam Man , Lam Paula Yeng Po
Published: April 2023

Supplementary Figure S8 - PDF file 110K, Effect of combination therapy of DZNep with AH-6CC-L2C/5-FC on EpCAM expression. Hep3B cells were treated with either AH-6CC-L2C (MOI 1) with 2 mM 5-FC, 10 microM DZNep or combination therapy with AH-6CC-L2C (MOI 1)/2 mM 5-FC and 10 microM DZNep for 72 h before subjected to FACS analysis with PE-conjugated mouse anti-human EpCAM (Miltenyi Biotec, Auburn, CA) using FACSCanton II (Becton Dickinson). PE-conjugated mouse IgG was used as the isotype control
Supplementary Figure 6 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
Authors: Cai Tian-Yu , Liu Xiao-Wen , Zhu Hong , Cao Ji , Zhang Jun , Ding Ling , Lou Jian-Shu , He Qiao-Jun , Yang Bo
Published: April 2023

PDF file - 89K, Figure S6. Overexpression of HIF-1α could weaken the synergistic effect of SN-38 and TPZ.